Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes

Gilles Montalescot, Leonardo Bolognese, Dariusz Dudek, Patrick Goldstein, Christian Hamm, Jean-Francois Tanguay, Jurrien M ten Berg, Debra L Miller, Timothy M Costigan, Jochen Goedicke, Johanne Silvain, Paolo Angioli, Jacek Legutko, Margit Niethammer, Zuzana Motovska, Joseph A Jakubowski, Guillaume Cayla, Luigi Oltrona Visconti, Eric Vicaut, Petr WidimskyACCOAST Investigators

Research output: Contribution to journalArticlepeer-review

509 Citations (Scopus)


Although P2Y12 antagonists are effective in patients with non-ST-segment elevation (NSTE) acute coronary syndromes, the effect of the timing of administration--before or after coronary angiography--is not known. We evaluated the effect of administering the P2Y12 antagonist prasugrel at the time of diagnosis versus administering it after the coronary angiography if percutaneous coronary intervention (PCI) was indicated.
Original languageEnglish
Pages (from-to)999-1010
Number of pages12
JournalNew England Journal of Medicine
Issue number11
Publication statusPublished - 12 Sep 2013


  • Double-Blind Method
  • Coronary Angiography
  • Humans
  • Percutaneous Coronary Intervention
  • Aged
  • Thiophenes
  • Hemorrhage
  • Piperazines
  • Premedication
  • Acute Coronary Syndrome
  • Coronary Artery Bypass
  • Purinergic P2Y Receptor Antagonists
  • Middle Aged
  • Myocardial Infarction
  • Female
  • Male

Cite this